Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Katsuyuki Hotta

Current Evidence and Future Perspectives of Immune-Checkpoint Inhibitors in Unresectable Malignant Pleural Mesothelioma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

ILD During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2010English

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2010English

Exploration of Resistance Mechanisms for EGFR-TKIs Based on Plasma Analysis by Digital PCR and Next-Generation Sequencing

Cancer Science
Cancer ResearchMedicineOncology
2018English

MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib

Scientific Reports
Multidisciplinary
2018English

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review

PLoS ONE
Multidisciplinary
2011English

A Prospective Cohort Study to Define the Clinical and Pathological Features of Lung Cancers Harboring HER2 Gene Aberrations (The HER2-CS Study) and a Phase II Study of Trastuzumab Emtansine (Recombinant) in Patients With HER2-positive Non-Small Cell Lung Cancer Who Recurred, Progressed After Standard Chemotherapy, or Were Primarily Refractory to Standard Chemotherapy

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
2015English

Publication of Lung Cancer Clinical Trials in Japan

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy